Spiriva HandiHaler tiotropium: Phase IV data

A double-blind, U.S. and Canadian Phase IV trial (205.440) in 126 patients with mild to moderate COPD showed that once-daily 18 µg Spiriva HandiHaler tiopropium significantly improved mean isotime inspiratory capacity, the

Read the full 323 word article

User Sign In